Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation positive unresectable or metastatic melanoma (MM) Meeting Abstract

  

Authors:	Puzanov, I.; Callahan, M. K.; Linette, G. P.; Patel, S. P.; Luke, J. J.; Sosman, J. A.; Wolchok, J. D.; Hamid, O.; Minor, D. R.; Orford, K. W.; Hug, B. A.; Ma, B.; Matthys, G. M.; Hoos, A.
Abstract Title:	Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation positive unresectable or metastatic melanoma (MM)
Meeting Title:	50th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	32
Issue:	15 Suppl.
Meeting Dates:	2014 May 30-Jun 3
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2014-05-20
Language:	English
ACCESSION:	WOS:000358613202776
PROVIDER:	wos
DOI:	10.1200/jco.2014.32.15_suppl.2511
Notes:	Meeting Abstract: 2511 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/81025